行情

ITRM

ITRM

Iterum Therapeutics plc
NASDAQ

实时行情|Nasdaq Last Sale

3.360
-0.600
-15.15%
休市 16:00 10/18 EDT
开盘
4.000
昨收
3.960
最高
4.049
最低
3.360
成交量
2.88万
成交额
--
52周最高
9.30
52周最低
3.360
市值
4,415.97万
市盈率(TTM)
-0.5000
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ITRM 新闻

  • 全球衰退担忧加剧 IMF料明年美日欧经济状况改善不大
  • 新浪美股.12分钟前
  • 高盛投资银行家被控内幕交易被捕 非法获利260万美元
  • 新浪美股.1小时前
  • 通用汽车罢工刚结束 沃尔沃麦克卡车工厂也开始罢工
  • 新浪美股.1小时前
  • "既当球员又当裁判"?波音工程师的"双重身份"引担忧
  • 新浪美股.1小时前

更多

所属板块

生物技术和医学研究
-1.17%
制药与医学研究
-0.94%

热门股票

名称
价格
涨跌幅

ITRM 简况

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The Company is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The Company is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. It is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. It has demonstrated potent in vitro activity against all genera of Enterobacteriacease, in anaerobes such as Bacteroides, Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus, gram-positive organisms including methicillin-susceptible staphylococci, Streptococcus pyogenes and Streptococcus pneumonia.
展开

Webull提供Iterum Therapeutics PLC的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。